Navigation Links
Sinovac Reports Unaudited First Quarter 2009 Financial Results
Date:5/15/2009

5,549,684 5,549,684 Accumulated deficit (1,626,855) (1,651,534) Total shareholders' equity 49,550,212 49,713,775 Noncontrolling interest 7,297,929 7,185,349 Total equity 56,848,141 56,899,124 Total liabilities and equity $80,941,570 $83,203,222 SINOVAC BIOTECH LTD. Incorporated in Antigua and Barbuda Consolidated Statements of Operations and Comprehensive Income Three months ended March 31, 2009 and 2008 Unaudited (Expressed in U.S. Dollars) 2009 2008 Sales $6,566,099 $8,862,001 Cost of sales exclusive of depreciation of land use right and amortization of licenses and permits of $104,633 (2008 - $99,834) 1,447,770 1,047,866 Gross Profit 5,118,329 7,814,135 Selling, general and administrative expenses 3,547,623 3,577,886 Research and development expenses net of $58,311(2008 - $4,019) in government research grants 759,441 929,336 Depreciation of property, plant and equipment and amortization of licenses and permits 164,869 178,229 Total Operating Expenses 4,471,933 4,685,451 Operating Income 646,396 3,128,684 Interest and financing expenses (126,200) (157,707) Interest and other income 93,131 46,350 Income before income taxes 613,327 3,017,327 Income taxes expenses
'/>"/>
SOURCE Sinovac Biotech Ltd.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine news :

1. Sinovac to Present at the Brean Murray, Carret & Co. Fourth Investor Tour of China
2. Sinovac Provides Support to Chinas Ministry of Health to Aid Earthquake Victims
3. Sinovac Announces that Government Investigation Rules Out Healives Role in Childs Death
4. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
5. Haemacure Reports Third Quarter 2007 Results
6. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
7. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
8. MDS Reports Third Quarter 2007 Results
9. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
10. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
11. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Biomatrica Launches DNAgard(TM) for Room Temperature Storage of Tissues and Cell Culture 2Biomatrica Launches DNAgard(TM) for Room Temperature Storage of Tissues and Cell Culture 3Rib-X Pharmaceuticals Expands License Agreement with Yale University on New Ribosome Technology 2Undocumented Hispanics Face Health Care Roadblocks in U S 60405 1Undocumented Hispanics Face Health Care Roadblocks in U S 60405 2Anesiva Announces Date for 2009 Annual Meeting of Stockholders to Vote on Proposed Merger 60400 1Anesiva Announces Date for 2009 Annual Meeting of Stockholders to Vote on Proposed Merger 60400 2Anesiva Announces Date for 2009 Annual Meeting of Stockholders to Vote on Proposed Merger 60400 3BMP Sunstone Announces November Investor Conference Participation 14664 1BMP Sunstone Announces November Investor Conference Participation 14664 2